G&S Capital’s Novo Nordisk NVO Stock Holding History

G&S Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-452	Closed	-$13K	–	151
2020 Q1	$13K	Hold	452	–	–	0.02%	127
2019 Q4	$13K	Hold	452	–	–	0.01%	174
2019 Q3	$12K	Hold	452	–	–	0.01%	161
2019 Q2	$12K	Hold	452	–	–	0.01%	174
2019 Q1	$12K	Buy	+452	New	+$11.1K	0.01%	165

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

G&S Capital's NVO Position: Q2 2020 in Review

G&S Capital sold out of Novo Nordisk (NVO) in Q2 2020, closing a stake of 452 shares — an estimated $13K sold.

G&S Capital first reported a position in NVO in Q1 2019 and held it in 5 quarters. The position peaked at $13K in Q1 2020. 660 funds tracked by Wall St. Rank hold NVO as of Q2 2020.

G&S Capital reported no remaining Novo Nordisk position as of Q2 2020 after selling out during the quarter.
G&S Capital sold 452 Novo Nordisk shares in Q2 2020, an estimated $13K.
G&S Capital first reported a position in Novo Nordisk in Q1 2019 and held it in 5 quarters.
G&S Capital's Novo Nordisk position peaked at $13K in Q1 2020.
660 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2020.

Based on G&S Capital's 13F filing for Q2 2020, filed 24 Jul 2020.